The chaperone-like activity can link the anti-apoptotic roles and beneficial metabolic effect of SHLP2 against IAPP aggregation, suggesting that SHLP2 has potential as a T2D therapeutic. The gene discussed is IAPP; the disease is type 2 diabetes mellitus.